How Clinical Measures Accelerate Alzheimer's Disease Drug Development

Clinical Scientist, Jen Blankenship, PhD., presented at the 2022 Digital Biomarkers and Clinical Measures in Neurology conference to discuss the significant opportunities to advance Alzheimer’s Disease drug development with wearable and connected technology. Watch Jen's on-demand presentation to learn more about:

• Addressing an unmet need in Alzheimer’s disease clinical trials using digital clinical measures
• Translating meaningful aspects of health in Alzheimer’s disease to measurable digital outcomes
• Promising candidate digital clinical measures and key steps to facilitate their acceptance in Alzheimer’s disease drug development

There is a need to identify novel patient-centric endpoints that advance drug development and deliver treatments to improve the lives of patients who need them.

Fill out the form to watch the presentation and download the slides now.